- Goldman Sachs has initiated coverage on Innate Pharma (IPHYF) and added the company to its buy conviction list, sending its shares up 41% to €10.8 in Paris.
- Goldman also gave Innate a price target of €18,
- Innate specializes in the development of immunotherapy drugs for the treatment of cancer and inflammatory diseases.
Innate added to Goldman conviction list, shares soar
Feb 4 2014, 09:15 ET